Precise and targeted healthcare interventions are invaluable in ensuring better outcomes for patients. Investing in innovative research to uncover biomarkers and personalized treatment approaches is at the heart of precision health. In this regard, we are pleased to highlight Dr. Walsh‘s recent achievement of receiving an internal grant from the ICTS – Precision Health Innovation Awards, specifically titled ‘Biomarkers of Uveitic Macular Edema Response to Topical NSAIDs’.
Dr. Walsh’s project, funded by the Precision Health Innovation Awards program, aims to advance initial discovery pilots in the field of uveitic macular edema. Uveitic macular edema is a condition characterized by fluid accumulation in the retina, leading to vision impairment. The study focuses on investigating biomarkers that can predict how patients with uveitic macular edema respond to topical NSAIDs (non-steroidal anti-inflammatory drugs). By identifying biomarkers associated with treatment response, tailored approaches to managing this condition can be developed.
The Precision Health Innovation Awards, administered by the Institute of Clinical and Translational Sciences (ICTS), provide crucial support to investigators engaged in pioneering research. This funding opportunity aims to facilitate early-stage work, including pilot data collection and analysis, with the ultimate goal of obtaining external funding in the future. The grant awarded to Dr. Walsh spans from March 1, 2024, to February 28, 2025, enabling a year of intensive investigative work.
James Walsh, MD, PhD
Assistant Professor, Ophthalmology and Visual Sciences
- Email: walsh.j@nospam.wustl.edu